Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01382
|
|||||
| Drug Name |
Alfuzosin
|
|||||
| Synonyms |
Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Benign prostatic hyperplasia [ICD11:GA90] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H27N5O4
|
|||||
| Canonical SMILES |
CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
|
|||||
| InChI |
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
|
|||||
| InChIKey |
WNMJYKCGWZFFKR-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 81403-80-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 389.4 | Topological Polar Surface Area | 112 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
1.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
7348779
,7978547
,8151421
,11371965
,11374754
,11466350
,11467470
,11484165
,11485980
,11488321
,11490878
,11493022
,14805133
,26612860
,26680540
,26719847
,26749009
,26749010
,29221272
,46386655
,46508512
,47509539
,47656603
,47730752
,47879632
,48029201
,48328565
,49681674
,49699344
,49971151
,50107503
,50107504
,50315525
,51091463
,56464294
,57321133
,81092780
,85209969
,85788468
,85789670
,90341616
,92124875
,92308116
,92308400
,103194715
,103941451
,104299580
,117887447
,124637420
,124658863
|
|||||
| ChEBI ID |
ChEBI:51141
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Alfuzosin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.